Enliven Therapeutics (ELVN) TD Cowen 46th Annual Health Care Conference summary

Company overview and leadership transition

• Company is in a strong position, focusing on advancing ELVN-001 into its first phase 3 study this year.

• Leadership change was driven by the need for late-stage development and commercialization expertise.

• New CEO brings extensive commercial and late-stage oncology experience.

Clinical development and data highlights

• ELVN-001 showed strong efficacy in heavily pretreated CML patients, with MMR rates between 38% and 53% in different cohorts.

• Safety profile is favorable, with low discontinuation rates and no new safety signals.

• Data maturity and patient population are critical for interpreting efficacy results.

• Updated phase 1 data will be presented at EHA in June, with regulatory interactions expected midyear.

Competitive positioning and market strategy

• ELVN-001 is positioned for second-line plus use, targeting patients post-asciminib.

• Molecule is ATP-competitive, potentially offering advantages over allosteric agents in resistant populations.

• Long-term strategy includes moving into frontline CML, pending regulatory input and additional safety data.

• Market opportunity in the US is estimated at $9 billion, with half in second-line plus.